相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target
Michael T. Werner et al.
BLOOD (2017)
Visfatin mediates doxorubicin resistance in human non-small-cell lung cancer via Akt-mediated up-regulation of ABCC1
Zhili Cao et al.
CELL PROLIFERATION (2017)
Hydrazinyldiene-chroman-2,4-diones in inducing growth arrest and apoptosis in breast cancer cells: Synergism with doxorubicin and correlation with physicochemical properties
Lulzime Ballazhi et al.
ACTA PHARMACEUTICA (2017)
Genetics of anaplastic large cell lymphoma
Yu Zeng et al.
LEUKEMIA & LYMPHOMA (2016)
Adult systemic anaplastic large-cell lymphoma: recommendations for diagnosis and management
Nabila Bennani-Baiti et al.
EXPERT REVIEW OF HEMATOLOGY (2016)
Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma
Thibault Dupont et al.
ONCOTARGET (2016)
Anaplastic large cell lymphoma in paediatric and young adult patients
Suzanne D. Turner et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor
Cameron T. Durlacher et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2016)
Increasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism
Ann-Marie Meredith et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2016)
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
Sara Redaelli et al.
ONCOTARGET (2016)
Insights into the Pathogenesis of Anaplastic Large-Cell Lymphoma through Genome-wide DNA Methylation Profiling
Melanie R. Hassler et al.
CELL REPORTS (2016)
The biology and management of systemic anaplastic large cell lymphoma
Greg Hapgood et al.
BLOOD (2015)
limma powers differential expression analyses for RNA-sequencing and microarray studies
Matthew E. Ritchie et al.
NUCLEIC ACIDS RESEARCH (2015)
Successful treatment of relapsed anaplastic large cell lymphoma with vinblastine monotherapy and allo-HSCT with reduced intensity conditioning regimen
Satoshi Miyagaki et al.
PEDIATRICS INTERNATIONAL (2015)
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation
F. Abate et al.
LEUKEMIA (2015)
STRING v10: protein-protein interaction networks, integrated over the tree of life
Damian Szklarczyk et al.
NUCLEIC ACIDS RESEARCH (2015)
Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease
Toby A. Eyre et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase-Positive Lymphoma Patients
Carlo Gambacorti Passerini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Advanced Stage Anaplastic Large Cell Lymphoma in Children and Adolescents: Results of ANHL0131, a Randomized Phase III Trial of APO Versus a Modified Regimen With Vinblastine: A Report From the Children's Oncology Group
Sarah Alexander et al.
PEDIATRIC BLOOD & CANCER (2014)
microRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma
Cuiling Liu et al.
BLOOD (2013)
Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma
Ju Gao et al.
BMC CANCER (2013)
Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma
Fabrizio Tabbo et al.
CURRENT OPINION IN HEMATOLOGY (2013)
Differential expression of aurora-A kinase in T-cell lymphomas
Rashmi Kanagal-Shamanna et al.
MODERN PATHOLOGY (2013)
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
Yael P. Mosse et al.
LANCET ONCOLOGY (2013)
Identification of C/EBPβ Target Genes in ALK plus Anaplastic Large Cell Lymphoma (ALCL) by Gene Expression Profiling and Chromatin Immunoprecipitation
Irina Bonzheim et al.
PLOS ONE (2013)
Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex
Rocco Piazza et al.
NEOPLASIA (2013)
The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update
Raymond Lai et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2013)
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Barbara Pro et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Prognostic Impact of Morphologic and Phenotypic Features of Childhood ALK-Positive Anaplastic Large-Cell Lymphoma: Results of the ALCL99 Study
Laurence Lamant et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Doxorubicin pathways: pharmacodynamics and adverse effects
Caroline F. Thorn et al.
PHARMACOGENETICS AND GENOMICS (2011)
Immunohistochemical expression of Mum-1, Oct-2 and Bcl-6 in systemic anaplastic large cell lymphomas
Arzu Saglam et al.
TUMORI (2011)
Vinblastine in Children and Adolescents With High-Risk Anaplastic Large-Cell Lymphoma: Results of the Randomized ALCL99-Vinblastine Trial
Marie-Cecile Le Deley et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Studies of Phosphoproteomic Changes Induced by Nucleophosmin-Anaplastic Lymphoma Kinase (ALK) Highlight Deregulation of Tumor Necrosis Factor (TNF)/Fas/TNF-related Apoptosis-induced Ligand Signaling Pathway in ALK-positive Anaplastic Large Cell Lymphoma
Fang Wu et al.
MOLECULAR & CELLULAR PROTEOMICS (2010)
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
Anas Younes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Anaplastic lymphoma kinase: signalling in development and disease
Ruth H. Palmer et al.
BIOCHEMICAL JOURNAL (2009)
A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma
Andres Forero-Torres et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Dual Therapeutic Efficacy of Vinblastine as a Unique Chemotherapeutic Agent Capable of Inducing Dendritic Cell Maturation
Hiroaki Tanaka et al.
CANCER RESEARCH (2009)
Upregulation of the CDC25A phosphatase down-stream of the NPM/ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation
Anne Fernandez-Vidal et al.
CELL CYCLE (2009)
Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy
Thomas R. Webb et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2009)
Single-Drug Vinblastine As Salvage Treatment for Refractory or Relapsed Anaplastic Large-Cell Lymphoma: A Report From the French Society of Pediatric Oncology
Laurence Brugieres et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma
S. Eckerle et al.
LEUKEMIA (2009)
The expression of granulysin in systemic anaplastic large cell lymphoma in childhood
Noriko Kitamura et al.
LEUKEMIA RESEARCH (2009)
Gene deregulation and spatial genome reorganization near breakpoints prior to formation of translocations in anaplastic large cell lymphoma
Stephan Mathas et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
STAT3-mediated up-regulation of BLIMP1 is coordinated with BCL6 down-regulation to control human plasma cell differentiation
Sean A. Diehl et al.
JOURNAL OF IMMUNOLOGY (2008)
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
Michal Marzec et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
James G. Christensen et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Pathobiology of ALK+ anaplastic large-cell lymphoma
Hesham M. Amin et al.
BLOOD (2007)
CD30 activates both the canonical and alternative NF-κB pathways in anaplastic large cell lymphoma cells
Casey W. Wright et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes
Laurence Lamant et al.
BLOOD (2007)
The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner
Faye Yuan-Yi Hsu et al.
CANCER RESEARCH (2006)
Reappraisal of BCL3 as a molecular marker of anaplastic large cell lymphoma
H Ohno et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2005)
Advanced-stage large-cell lymphoma in children and adolescents: Results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: A Pediatric Oncology Group phase III trial
JH Laver et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms -: Intermediacy of H2O2- and p53-dependent pathways
SW Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity
JA Francisco et al.
BLOOD (2003)
The nucleophosmin-anaplastic lymphoma kinase fusion protein induces c-myc expression in pediatric anaplastic large cell lymphomas
EA Raetz et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children's Cancer Study Group chemotherapy regimens
DM Williams et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma:: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90
K Seidemann et al.
BLOOD (2001)
BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control
AL Shaffer et al.
IMMUNITY (2000)
Relapses of childhood anaplastic large-cell lymphoma: Treatment results in a series of 41 children - A report from the French Society of Pediatric Oncology
L Brugieres et al.
ANNALS OF ONCOLOGY (2000)
分享论文
